✦ LIBER ✦

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCS

✍ Scribed by A. Österborg; A. Ahre; M. Björkholm; M. Björeman; G. Brenning; G. Gahrton; H. Gyllenhammar; B. Johansson; G. Juliusson; M. Järnmark; A. Killander; E. Kimby; R. Lerner; B. Nilsson; C. Paul; B. Simonsson; A.-M. Stalfelt; H. Strander; B. Smedmyr; E. Svedmyr; A.-M. Udén; B. Wadman; C. Wedelin; H. Mellstedt

Book ID: 114791172
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 495 KB
Volume: 43
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1989.tb01252.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB